New drug may protect breast cancer patients from dangerous infection risk
NCT ID NCT07380646
First seen Feb 02, 2026 · Last updated May 22, 2026 · Updated 17 times
Summary
This study tests whether a drug called leucogen can prevent severe neutropenia (dangerously low white blood cell counts) in women with early-stage hormone receptor-positive, HER2-negative breast cancer who are receiving ribociclib plus hormone therapy. About 94 participants will receive leucogen at the start of each treatment cycle. The goal is to see if this reduces the risk of infections and allows patients to stay on their cancer treatment without delays.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Breast surgery department
RECRUITINGHangzhou, Zhejiang, 310058, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.